Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test

Brazilian Journal of Psychiatry, Journal Year: 2018, Volume and Issue: 41(1), P. 9 - 14

Published: Oct. 17, 2018

Objective: Cannabidiol (CBD), one of the non-psychotomimetic compounds Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped dose-response curves. No study, however, has investigated whether increasing doses this drug would also cause similar curves humans. The objective study was to compare acute different CBD and placebo healthy volunteers performing a simulated public speaking test (SPST), well-tested anxiety-inducing method. Method: A total 57 male subjects were allocated receive oral at 150 mg (n=15), 300 600 (n=12) or (n=15) double-blind procedure. During SPST, subjective ratings on Visual Analogue Mood Scale (VAMS) physiological measures (systolic diastolic blood pressure, heart rate) obtained six time points. Results: Compared placebo, pretreatment significantly reduced anxiety during speech. significant differences VAMS scores observed between groups receiving mg, placebo. Conclusion: Our findings confirm properties are consonant results animal studies describing Optimal therapeutic should be rigorously determined so that research can adequately translated into clinical practice.

Language: Английский

---

A systematic review of cannabidiol dosing in clinical populations

British Journal of Clinical Pharmacology, Journal Year: 2019, Volume and Issue: 85(9), P. 1888 - 1900

Published: June 21, 2019

Aims Cannabidiol (CBD) is a cannabis‐derived medicinal product with potential application in wide‐variety of contexts; however, its effective dose different disease states remains unclear. This review aimed to investigate what doses have been applied clinical populations, order understand the active range CBD variety medical contexts. Methods Publications involving administration alone were collected by searching PubMed, EMBASE and ClinicalTrials.gov . Results A total 1038 articles retrieved, which 35 studies met inclusion criteria covering 13 Twenty‐three reported significant improvement primary outcomes (e.g. psychotic symptoms, anxiety, seizures), ranging between <1 50 mg/kg/d. Plasma concentrations not provided any publication. was as well tolerated epilepsy most frequently studied condition, all 11 demonstrating positive effects on reducing seizure frequency or severity (average 15 mg/kg/d within randomised controlled trials). There no signal activity small trials (range n = 6–62) assessing diabetes, Crohn's disease, ocular hypertension, fatty liver chronic pain. However, low 2.4 mg/kg/d) used these studies. Conclusion highlights that has wide several pathologies. Pharmacokinetic conclusive phase III elucidate plasma contexts are severely lacking highly encouraged.

Language: Английский

---

Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update

International Journal of Drug Policy, Journal Year: 2021, Volume and Issue: 99, P. 103381 - 103381

Published: Aug. 28, 2021

Cannabis use is common, especially among young people, and associated with risks for various health harms. Some jurisdictions have recently moved to legalization/regulation pursuing public goals. Evidence-based 'Lower Risk Use Guidelines' (LRCUG) recommendations were previously developed reduce modifiable risk factors of cannabis-related adverse outcomes; related evidence has evolved substantially since. We aimed review new scientific develop comprehensively up-to-date LRCUG, including their recommendations, on this basis. Targeted searches literature (since 2016) main outcomes by the user-individual conducted. Topical areas informed previous LRCUG content expanded upon current evidence. Searches preferentially focused systematic reviews, supplemented key individual studies. The results evidence-graded, topically organized narratively summarized; through an iterative expert consensus development process. A substantial body cannabis use-related harms identified varying quality. Twelve substantive recommendation clusters three precautionary statements developed. In general, suggests that individuals can if they delay onset until after adolescence, avoid high-potency (THC) products high-frequency/-intensity use, refrain from smoking-routes administration. While people are particularly vulnerable harms, other sub-groups (e.g., pregnant women, drivers, older adults, those co-morbidities) advised exercise particular caution risks. Legal/regulated should be used where possible. result in outcomes, mostly higher-risk use. Reducing help offer one targeted intervention component within a comprehensive approach They require effective audience-tailoring dissemination, regular updating as become available, evaluated impact.

Language: Английский

---

Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process

Journal of Cannabis Research, Journal Year: 2021, Volume and Issue: 3(1)

Published: July 2, 2021

Globally, medical cannabis legalization has increased in recent years and is commonly used to treat chronic pain. However, there are few randomized control trials studying indicating expert guidance on how dose administer safely effectively needed.Using a multistage modified Delphi process, twenty global experts across nine countries developed consensus-based recommendations patients with pain.There was consensus that may be considered for experiencing neuropathic, inflammatory, nociplastic, mixed Three treatment protocols were developed. A routine protocol where the clinician initiates patient CBD-predominant variety at of 5 mg CBD twice daily titrates by 10 every 2 3 days until reaches their goals, or up 40 mg/day. At mg/day, clinicians consider adding THC 2.5 titrate 7 maximum mg/day THC. conservative once 1 rapid balanced THC:CBD 2.5-5 each cannabinoid his/her goals mg/day.In summary, using

Language: Английский

---

Efficacy of cannabidiol alone or in combination with Δ‐9‐tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence

Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 13, 2025

Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related

Language: Английский

---

Access to cannabidiol without a prescription: A cross-country comparison and analysis

International Journal of Drug Policy, Journal Year: 2020, Volume and Issue: 85, P. 102935 - 102935

Published: Sept. 9, 2020

Recent legislative change has allowed increased access to cannabis products in many jurisdictions. In some locations, this includes over-the-counter (OTC) and/or online containing cannabidiol (CBD), a non-intoxicating cannabinoid with therapeutic properties. Here we compared the availability of CBD and associated regulatory background nine selected countries. Accessibility was examined USA, Canada, Germany, Ireland, United Kingdom, Switzerland, Japan, Australia, New Zealand as May 2020. Regulatory other relevant documents were obtained from government agency websites related sources. Relevant commercial physical retailers visited verify CBD-containing nature available. A range appeared be accessible without prescription seven out countries reviewed. Australia exceptions where clinician required any product. commonly available included oils, gel capsules, purified crystal topical products. The daily recommended doses orally administered non-prescription typically well below 150 mg substantially lower than reported have effects published clinical trials (e.g., 300-1500 mg). legal foundations enabling several often unclear, marketed sometimes failing meet requirements for sale. There an obvious disparity between federal directives both USA European examined. are variety approaches how manage Many appear permit OTC but clarity. As consumer demand escalates, improved legislation, guidelines quality control would seem prudent together exploring benefits lower-dose formulations.

Language: Английский

---

Cannabidiol use and effectiveness: real-world evidence from a Canadian medical cannabis clinic

Journal of Cannabis Research, Journal Year: 2021, Volume and Issue: 3(1)

Published: June 23, 2021

Abstract Background Cannabidiol (CBD) is a primary component in the cannabis plant; however, recent years, interest CBD treatments has outpaced scientific research and regulatory advancement resulting confusing landscape of misinformation unsubstantiated health claims. Within limited results from randomized controlled trials, lack trust product quality known clinical guidelines dosages, real-world evidence (RWE) countries with robust frameworks may fill critical need for patients healthcare professionals. Despite growing interest, no data (RWD) studies have yet investigated patients’ reports impact on symptom control common expression pain, anxiety, depression, poor wellbeing. The objective this study to assess CBD-rich treatment burden, as measured specific assessment scale (ESAS-r). Methods This retrospective observational examined depression symptoms, wellbeing 279 participants over 18 years old, prescribed at network clinics dedicated medical Quebec, Canada. Data were collected baseline, 3 (FUP1), 6 (FUP2) month after initiation. Groups formed based severity (mild vs moderate/severe) changes plan FUP1 (CBD THC:CBD). Two-way mixed ANOVAs used ESAS-r scores differences between groups visits. Results All average decreased baseline (all p s < 0.003). addition delta-9-tetrahydrocannabinol (THC) during first follow-up had effect changes. Patients moderate/severe symptoms experienced important improvement 0.001), whereas those mild actually increased. Differences FUP2 not statistically different. Conclusion suggests beneficial well overall only moderate severe symptoms; observed symptoms. contribute address myths about demand further investigation.

Language: Английский

---

The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence

Clinical and Translational Science, Journal Year: 2022, Volume and Issue: 16(1), P. 10 - 30

Published: Oct. 19, 2022

Global interest in the non-intoxicating cannabis constituent, cannabidiol (CBD), is increasing with claims of therapeutic effects across a diversity health conditions. At present, there sufficient clinical trial evidence to support use high oral doses CBD (e.g., 10-50 mg/kg) treating intractable childhood epilepsies. However, question remains as whether "low-dose" products confer any benefits. This an important answer, low-dose are widely available many countries, often nutraceutical formulations. The present review therefore evaluated efficacy and safety low CBD. includes interventional studies that measured condition and/or tolerability dosed at less than or equal 400 mg per day adult populations (i.e., ≥18 years age). Studies were excluded if product administered had Δ

Language: Английский

---

Drug–Drug Interactions of Cannabidiol with Standard-of-Care Chemotherapeutics

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(3), P. 2885 - 2885

Published: Feb. 2, 2023

Cannabidiol (CBD) is an easily accessible and affordable Marijuana (Cannabis sativa L.) plant derivative with extensive history of medical use spanning thousands years. Interest in the therapeutic potential CBD has increased recent years, including its anti-tumour properties various cancer models. In addition to direct anticancer effects CBD, preclinical research on numerous cannabinoids, highlighted their in: (i) attenuating chemotherapy-induced adverse (ii) enhancing efficacy some drugs. Therefore, gaining popularity as a supportive therapy during treatment, often combination standard-of-care chemotherapeutics. However, biologically active substance that modulates cellular targets, thereby possibly resulting unpredictable outcomes, especially combinations other medications modalities. this review, we summarize current knowledge interactions selected chemotherapeutics, discuss emerging mechanistic basis for observed biological effects, highlight both benefits risks such combined treatments. Apart from experimental results, also indicate planned or ongoing clinical trials aiming evaluate impact oncology. The results these future are essential provide better guidance oncologists judge benefit-versus-risk ratio exciting treatment strategies. We hope our present overview rapidly advancing field biomedicine will inspire more studies further understanding underlying biology optimize patients.

Language: Английский

---

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

Journal of Clinical Medicine, Journal Year: 2019, Volume and Issue: 8(7), P. 1058 - 1058

Published: July 19, 2019

The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use (SUDs). non-psychoactive compound, cannabidiol (CBD) is a highly promising tool treatment disorders. Here we review human clinical studies that investigated efficacy CBD for schizophrenia, disorders, their comorbidity. In particular, examined possible profiles patients who may benefit most from treatment. CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms with particularly effects early stages illness. A potential biomarker level anandamide blood. THC mixtures showed positive reducing short-term withdrawal craving cannabis Studies on schizophrenia comorbid are lacking. Future should focus different illness, together use. These standardized measures assess addition, future efforts be taken study relationship between eCB system, GABA/glutamate, immune reveal underlying neurobiology CBD.

Language: Английский

---